Antibody-Based Fusion Proteins
Inventor(s): Gillies et al.
Serial No. Not Yet Assigned
Atty Docket No. LEX-011

Atty/Agent: Patrick R. H. Waller
Express Mail Label No. EL280660274US

Pharmacokinetics of KS-IL-2 with junction alterations (IL-2 ELISA)




Figure 1A

COVERTE CECAL

APPROVED	O.G. FIG.		
BY	CLASS	SUBCLASS	
DRAFTSMAN			

m

D

Title: Enhancing the Circulating Half-Life of

Antibody-Based Fusion Proteins Inventor(s): Gillies et al. Serial No. Not Yet Assigned Atty Docket No. LEX-011 Atty/Agent: Patrick R. H. Waller Express Mail Label No. EL280660274US

Effect of alteration of fusion junction on pharmacokinetics of KS-IL-2 (Fc ELISA)




Figure 1B

	P			
		O.G. FIG.		
i	BY	CLASS	SUBCLASS	
	DRAFTSMAN	-)		

m

Ü

Title: Enhancing the Circulating Half-Life of Antibody-Based Fusion Proteins Inventor(s): Gillies et al.
Serial No. Not Yet Assigned
Atty Docket No. LEX-011
Atty/Agent: Patrick R. H. Waller
Express Mail Label No. EL280660274US

Pharmacokinetics of KS-IL-2 fusions in wildtype and beta2 mutant mice




Figure 2

·				
APPROVED	O.G. FIG.			
BY	CLASS	SUBCLASS		
DRAFTSMAN				

Title: Enhancing the Circulating Half-Life of Antibody-Based Fusion Proteins Inventor(s): Gillies et al. Serial No. Not Yet Assigned Atty Docket No. LEX-011 Atty/Agent: Patrick R. H. Waller Express Mail Label No. EL280660274US

Pharmacokinetics of antibody-TNFalpha





Figure 3



M

n

Ħ

fitle: Enhancing the Circulating Hait=Lite of Antibody-Based Fusion Proteins Inventor(s): Gillies et al. Serial No. Not Yet Assigned Atty Docket No. LEX-011 Atty/Agent: Patrick R. H. Waller Express Mail Label No. EL280660274US

Binding of antibody-IL-2 fusion proteins to Fc receptor




Figure 4 (J774 binding)

Title: Enhancing the Circulating Half-Life of Antibody-Based Fusion Proteins Inventor(s): Gillies et al.
Serial No. Not Yet Assigned
Atty Docket No. LEX-011
Atty/Agent: Patrick R. H. Waller
Express Mail Label No. EL280660274US



